Apatinib as an alternative therapy for advanced hepatocellular carcinoma
| Autor: | Ti Zhang, Xiu-Xiu Li, Man-Qing Cao, Xi-Hao Zhang |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Hepatocellular carcinoma
medicine.drug_class Angiogenesis Alternative therapy Tyrosine-kinase inhibitor 03 medical and health sciences chemistry.chemical_compound Vascular endothelial growth factor receptor 2 0302 clinical medicine Medicine Apatinib Hepatology business.industry Minireviews Kinase insert domain receptor medicine.disease digestive system diseases Vascular endothelial growth factor chemistry 030220 oncology & carcinogenesis Cancer research 030211 gastroenterology & hepatology business Tyrosine kinase |
| Zdroj: | World Journal of Hepatology |
| ISSN: | 1948-5182 |
| DOI: | 10.4254/wjh.v12.i10.766 |
| Popis: | Angiogenesis plays an important role in the occurrence and development of tumors. Registered tyrosine kinase inhibitors targeting vascular endothelial growth factor reduce angiogenesis. Apatinib, a tyrosine kinase inhibitor, can specifically inhibit vascular endothelial growth factor receptor 2, showing encouraging anti-tumor effects in a variety of tumors including advanced hepatocellular carcinoma (HCC). This article intends to review the clinical research and application prospects of apatinib in the field of HCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|